Advances in vasospasm treatment and prevention

Journal of the Neurological Sciences

Volumn 261, Issue 1-2, 2007, Pages 134-142

  Komotar, Ricardo J ^a   Zacharia, Brad E ^a   Valhora, Ricky ^a   Mocco, J ^a   Connolly Jr , E Sander ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Aneurysmal subarachnoid hemorrhage; Endovascular; Medical management; Therapy; Vasospasm

Indexed keywords

ANTIOXIDANT; CALCIUM ANTAGONIST; CD11 ANTIGEN; CD18 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; DISUFENTON SODIUM; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAGNESIUM SULFATE; METHYLPREDNISOLONE; NAFAMSTAT MESILATE; NICARAVIN; NICARDIPINE; NIMODIPINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; NITROPRUSSIDE SODIUM; PAPAVERINE; SCAVENGER; SIMVASTATIN; TRILIZAD MESYLATE; UNCLASSIFIED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANEURYSM; ARTERY STEAL SYNDROME; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROSPINAL FLUID DRAINAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; COST EFFECTIVENESS ANALYSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOVASCULAR SURGERY; FENESTRATION; HEMODILUTION; HUMAN; HYDROCEPHALUS; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INTERMETHOD COMPARISON; INTRACRANIAL PRESSURE; KIDNEY DISEASE; LUNG EDEMA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, BALLOON; ANTI-INFLAMMATORY AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE; SUBARACHNOID HEMORRHAGE; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 34548147894     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.04.046     Document Type: Article

References (136)

1. Broderick J.P., Brott T., Tomsick T., Huster G., and Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 326 (1992) 733-736
2. Ingall T., Asplund K., Mahonen M., and Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke 31 (2000) 1054-1061
3. Kiyohara Y., Ueda K., Hasuo Y., Wada J., Kawano H., Kato I., et al. Incidence and prognosis of subarachnoid hemorrhage in a Japanese rural community. Stroke 20 (1989) 1150-1155
4. Sarti C., Tuomilehto J., Salomaa V., Sivenius J., Kaarsalo E., Narva E.V., et al. Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke 22 (1991) 848-853
5. Hop J.W., Rinkel G.J., Algra A., and van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 28 (1997) 660-664
6. Broderick J.P., Brott T.G., Duldner J.E., Tomsick T., and Leach A. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 25 (1994) 1342-1347
7. Biller J., Godersky J.C., and Adams Jr. H.P. Management of aneurysmal subarachnoid hemorrhage. Stroke 19 (1988) 1300-1305
8. Treggiari-Venzi M.M., Suter P.M., and Romand J.A. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 48 (2001) 249-261 [discussion 61-2]
9. Kassell N.F., Helm G., Simmons N., Phillips C.D., and Cail W.S. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 77 (1992) 848-852
10. Romner B., and Reinstrup P. Triple H therapy after aneurysmal subarachnoid hemorrhage. A review. Acta Neurochir Suppl 77 (2001) 237-241
11. Solomon R.A., Fink M.E., and Lennihan L. Prophylactic volume expansion therapy for the prevention of delayed cerebral ischemia after early aneurysm surgery. Results of a preliminary trial. Arch Neurol 45 (1988) 325-332
12. Tettenborn D., and Dycka J. Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage. Stroke 21 (1990) IV85-IV89
13. Tettenborn D., Dycka J., Volberg E., and Dudden P. Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage. Neurochirurgia (Stuttg) 28 Suppl 1 (1985) 84-86
14. Murray G.D. Surgical bleeding and calcium antagonists. British aneurysm nimodipine trial reported improved clinical outcome with nimodipine. BMJ 311 (1995) 388-389
15. Pickard J.D., Murray G.D., Illingworth R., Shaw M.D., Teasdale G.M., Foy P.M., et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298 (1989) 636-642
16. Karinen P., Koivukangas P., Ohinmaa A., Koivukangas J., and Ohman J. Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery. Neurosurgery 45 (1999) 780-784 [discussion 84-5]
17. Flamm E.S., Adams Jr. H.P., Beck D.W., Pinto R.S., Marler J.R., Walker M.D., et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 68 (1988) 393-400
18. Haley Jr. E.C., Kassell N.F., and Torner J.C. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78 (1993) 537-547
19. Haley Jr. E.C., Kassell N.F., and Torner J.C. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg 78 (1993) 548-553
20. Haley Jr. E.C., Kassell N.F., Torner J.C., Truskowski L.L., and Germanson T.P. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80 (1994) 788-796
21. Macdonald R.L., Curry D.J., Aihara Y., Zhang Z.D., Jahromi B.S., and Yassari R. Magnesium and experimental vasospasm. J Neurosurg 100 (2004) 106-110
22. Veyna R.S., Seyfried D., Burke D.G., Zimmerman C., Mlynarek M., Nichols V., et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 96 (2002) 510-514
23. van den Bergh W.M., Algra A., van Kooten F., Dirven C.M., van Gijn J., Vermeulen M., et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 36 (2005) 1011-1015
24. Rinkel G.J., Feigin V.L., Algra A., van den Bergh W.M., Vermeulen M., and van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev (2005) CD000277
25. Biondi A., Ricciardi G.K., Puybasset L., Abdennour L., Longo M., Chiras J., et al. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol 25 (2004) 1067-1076
26. Song J.K., Elliott J.P., and Eskridge J.M. Neuroradiologic diagnosis and treatment of vasospasm. Neuroimaging Clin N Am 7 (1997) 819-835
27. Zubkov Y.N., Nikiforov B.M., and Shustin V.A. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien) 70 (1984) 65-79
28. Rosenwasser R.H., Armonda R.A., Thomas J.E., Benitez R.P., Gannon P.M., and Harrop J. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery 44 (1999) 975-979 [discussion 79-80]
29. Smith T.P., and Enterline D.S. Endovascular treatment of cerebral vasospasm. J Vasc Interv Radiol 11 (2000) 547-559
30. Fujii Y., Takahashi A., and Yoshimoto T. Effect of balloon angioplasty on high grade symptomatic vasospasm after subarachnoid hemorrhage. Neurosurg Rev 18 (1995) 7-13
31. Kobayashi H., Ide H., Aradachi H., Arai Y., Handa Y., and Kubota T. Histological studies of intracranial vessels in primates following transluminal angioplasty for vasospasm. J Neurosurg 78 (1993) 481-486
32. Megyesi J.F., Vollrath B., Cook D.A., Chen M.H., and Findlay J.M. Long-term effects of in vivo angioplasty in normal and vasospastic canine carotid arteries: pharmacological and morphological analyses. J Neurosurg 91 (1999) 100-108
33. Bejjani G.K., Bank W.O., Olan W.J., and Sekhar L.N. The efficacy and safety of angioplasty for cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 42 (1998) 979-986 [discussion 86-7]
34. Coyne T.J., Montanera W.J., Macdonald R.L., and Wallace MC. Percutaneous transluminal angioplasty for cerebral vasospasm after subarachnoid hemorrhage. Can J Surg 37 (1994) 391-396
35. Eskridge J.M., McAuliffe W., Song J.K., Deliganis A.V., Newell D.W., Lewis D.H., et al. Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 42 (1998) 510-516 [discussion 16-7]
36. Firlik A.D., Kaufmann A.M., Jungreis C.A., and Yonas H. Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 86 (1997) 830-839
37. Higashida R.T., Halbach V.V., Dowd C.F., Dormandy B., Bell J., and Hieshima G.B. Intravascular balloon dilatation therapy for intracranial arterial vasospasm: patient selection, technique, and clinical results. Neurosurg Rev 15 (1992) 89-95
38. Newell D.W., Eskridge J.M., Mayberg M.R., Grady M.S., and Winn H.R. Angioplasty for the treatment of symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg 71 (1989) 654-660
39. Klebanoff L.M., Fink M.E., Lennihan L., Solomon R.A., Mayer S., Beckford A.R., et al. Management of cerebral vasospasm in the 1990s. Clin Neuropharmacol 18 (1995) 127-137
40. Kaku Y., Yonekawa Y., Tsukahara T., and Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 77 (1992) 842-847
41. Firlik K.S., Kaufmann A.M., Firlik A.D., Jungreis C.A., and Yonas H. Intra-arterial papaverine for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Surg Neurol 51 (1999) 66-74
42. Kinoshita Y., Terada T., Nakamura Y., Nakai E., Nakai K., Itakura T., et al. Endovascular treatment of cerebral vasospasm with intra-arterial papaverine infusion. No Shinkei Geka 23 (1995) 881-887
43. McAuliffe W., Townsend M., Eskridge J.M., Newell D.W., Grady M.S., and Winn H.R. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg 83 (1995) 430-434
44. Numaguchi Y., and Zoarski G.H. Intra-arterial papaverine treatment for cerebral vasospasm: our experience and review of the literature. Neurol Med Chir (Tokyo) 38 (1998) 189-195
45. Polin R.S., Hansen C.A., German P., Chadduck J.B., and Kassell N.F. Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm. Neurosurgery 42 (1998) 1256-1264 [discussion 64-7]
46. Elliott J.P., Newell D.W., Lam D.J., Eskridge J.M., Douville C.M., Le Roux P.D., et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 88 (1998) 277-284
47. Dalbasti T., Karabiyikoglu M., Ozdamar N., Oktar N., and Cagli S. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 95 (2001) 44-50
48. Badjatia N., Topcuoglu M.A., Pryor J.C., Rabinov J.D., Ogilvy C.S., Carter B.S., et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 25 (2004) 819-826
49. Carhuapoma J.R., Qureshi A.I., Tamargo R.J., Mathis J.M., and Hanley D.F. Intra-arterial papaverine-induced seizures: case report and review of the literature. Surg Neurol 56 (2001) 159-163
50. Cross III D.T., Moran C.J., Angtuaco E.E., Milburn J.M., Diringer M.N., and Dacey Jr. R.G. Intracranial pressure monitoring during intraarterial papaverine infusion for cerebral vasospasm. AJNR Am J Neuroradiol 19 (1998) 1319-1323
51. Mathis J.M., Jensen M.E., and Dion J.E. Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Neuroradiology 39 (1997) 90-98
52. Numaguchi Y., Zoarski G.H., Clouston J.E., Zagardo M.T., Simard J.M., Aldrich E.F., et al. Repeat intra-arterial papaverine for recurrent cerebral vasospasm after subarachnoid haemorrhage. Neuroradiology 39 (1997) 751-759
53. Milburn J.M., Moran C.J., Cross III D.T., Diringer M.N., Pilgram T.K., and Dacey Jr. R.G. Increase in diameters of vasospastic intracranial arteries by intraarterial papaverine administration. J Neurosurg 88 (1998) 38-42
54. Babbitt D.G., Perry J.M., and Forman M.B. Intracoronary verapamil for reversal of refractory coronary vasospasm during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 12 (1988) 1377-1381
55. Pomerantz R.M., Kuntz R.E., Diver D.J., Safian R.D., and Baim D.S. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA. Cathet Cardiovasc Diagn 24 (1991) 283-285
56. Taniyama Y., Ito H., Iwakura K., Masuyama T., Hori M., Takiuchi S., et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 30 (1997) 1193-1199
57. Feng L., Fitzsimmons B.F., Young W.L., Berman M.F., Lin E., Aagaard B.D., et al. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol 23 (2002) 1284-1290
58. Murayama Y., Song J.K., Uda K., Gobin Y.P., Duckwiler G.R., Tateshima S., et al. Combined endovascular treatment for both intracranial aneurysm and symptomatic vasospasm. AJNR Am J Neuroradiol 24 (2003) 133-139
59. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 343 (1994) 1199-1206
60. Faraci F.M. Role of nitric oxide in regulation of basilar artery tone in vivo. Am J Physiol 259 (1990) H1216-H1221
61. Gabikian P., Clatterbuck R.E., Eberhart C.G., Tyler B.M., Tierney T.S., and Tamargo R.J. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: toxicity and efficacy studies in rabbits and rats. Stroke 33 (2002) 2681-2686
62. Hino A., Tokuyama Y., Weir B., Takeda J., Yano H., Bell G.I., et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery 39 (1996) 562-567 [discussion 67-8]
63. Pluta R.M., Oldfield E.H., and Boock R.J. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 87 (1997) 746-751
64. Pluta R.M., Thompson B.G., Dawson T.M., Snyder S.H., Boock R.J., and Oldfield E.H. Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg 84 (1996) 648-654
65. Thomas J.E., Nemirovsky A., Zelman V., and Giannotta S.L. Rapid reversal of endothelin-1-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurgery 40 (1997) 1245-1249
66. Thomas J.E., and Rosenwasser R.H. Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery 44 (1999) 48-57 [discussion 57-8]
67. Thomas J.E., Rosenwasser R.H., Armonda R.A., Harrop J., Mitchell W., and Galaria I. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke 30 (1999) 1409-1416
68. Afshar J.K., Pluta R.M., Boock R.J., Thompson B.G., and Oldfield E.H. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 83 (1995) 118-122
69. Dietrich H.H., and Dacey Jr. R.G. Molecular keys to the problems of cerebral vasospasm. Neurosurgery 46 (2000) 517-530
70. Macdonald R.L., and Weir B.K. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 22 (1991) 971-982
71. Heros R.C., Zervas N.T., Lavyne M.H., and Pickren K.S. Reversal of experimental cerebral vasospasm by intravenous nitroprusside therapy. Surg Neurol 6 (1976) 227-229
72. Hirsh L.F. Intra-arterial nitroprusside treatment of acute experimental vasospasm. Stroke 11 (1980) 601-605
73. Tierney T.S., Clatterbuck R.E., Lawson C., Thai Q.A., Rhines L.D., and Tamargo R.J. Prevention and reversal of experimental posthemorrhagic vasospasm by the periadventitial administration of nitric oxide from a controlled-release polymer. Neurosurgery 49 (2001) 945-951 [discussion 51-3]
74. Pradilla G., Thai Q.A., Legnani F.G., Hsu W., Kretzer R.M., Wang P.P., et al. Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. Neurosurgery 55 (2004) 1393-1399 [discussion 99-400]
75. Egemen N., Turker R.K., Sanlidilek U., Zorlutuna A., Bilgic S., Baskaya M., et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res 15 (1993) 310-315
76. Kistler J.P., Lees R.S., Candia G., Zervas N.T., Crowell R.M., and Ojemann R.G. Intravenous nitroglycerin in experimental cerebral vasospasm. A preliminary report. Stroke 10 (1979) 26-29
77. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic view of its actions. Crit Rev Neurosurg 9 (1999) 303-318
78. Ito Y., Isotani E., Mizuno Y., Azuma H., and Hirakawa K. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol 35 (2000) 45-50
79. Paulson O.B. Regional cerebral blood flow in apoplexy due to occlusion of the middle cerebral artery. Neurology 20 (1970) 63-77
80. Raabe A., Zimmermann M., Setzer M., Vatter H., Berkefeld J., and Seifert V. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 50 (2002) 1006-1013 [discussion 13-4]
81. Vajkoczy P., Horn P., Bauhuf C., Munch E., Hubner U., Ing D., et al. Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. Stroke 32 (2001) 498-505
82. Cosby K., Partovi K.S., Crawford J.H., Patel R.P., Reiter C.D., Martyr S., et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9 (2003) 1498-1505
83. Pluta R.M., Dejam A., Grimes G., Gladwin M.T., and Oldfield E.H. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 293 (2005) 1477-1484
84. Nilsson T., Cantera L., Adner M., and Edvinsson L. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery 40 (1997) 346-351 [discussion 51-3]
85. Kwan A.L., Bavbek M., Jeng A.Y., Maniara W., Toyoda T., Lappe R.W., et al. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg 87 (1997) 281-286
86. Nirei H., Hamada K., Shoubo M., Sogabe K., Notsu Y., and Ono T. An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci 52 (1993) 1869-1874
87. Cirak B., Kiymaz N., Ari H.H., and Ugras S. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm. Clin Auton Res 14 (2004) 197-201
88. Liu C.C., Chen Z.C., Cheng B.C., and Lin M.T. Prior antagonism of endothelin-1A receptors alleviates circulatory shock and cerebral ischemia during rat heatstroke. J Pharmacol Sci 96 (2004) 177-187
89. Clatterbuck R.E., Gailloud P., Ogata L., Gebremariam A., Dietsch G.N., Murphy K.J., et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 99 (2003) 376-382
90. Clatterbuck R.E., Oshiro E.M., Hoffman P.A., Dietsch G.N., Pardoll D.M., and Tamargo R.J. Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. J Neurosurg 97 (2002) 676-682
91. Mack W.J., Mocco J., Hoh D.J., Huang J., Choudhri T.F., Kreiter K.T., et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage. J Neurosurg 96 (2002) 71-75
92. Mocco J., Choudhri T.F., Mack W.J., Laufer I., Lee J., Kiss S., et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 48 (2001) 718-721 [discussion 21-2]
93. Mocco J., Mack W.J., Kim G.H., Lozier A.P., Laufer I., Kreiter K.T., et al. Rise in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 97 (2002) 537-541
94. Sercombe R., Dinh Y.R., and Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 88 (2002) 227-249
95. Bavbek M., Polin R., Kwan A.L., Arthur A.S., Kassell N.F., and Lee K.S. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 29 (1998) 1930-1935 [discussion 35-6]
96. Pradilla G., Wang P.P., Legnani F.G., Ogata L., Dietsch G.N., and Tamargo R.J. Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits. J Neurosurg 101 (2004) 88-92
97. Oshiro E.M., Hoffman P.A., Dietsch G.N., Watts M.C., Pardoll D.M., and Tamargo R.J. Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke 28 (1997) 2031-2037 [discussion 37-8]
98. Roux S., Breu V., Giller T., Neidhart W., Ramuz H., Coassolo P., et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283 (1997) 1110-1118
99. Kapiotis S., Sengoelge G., Sperr W.R., Baghestanian M., Quehenberger P., Bevec D., et al. Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Sci 58 (1996) 2167-2181
100. Nielsen V.G., and Webster R.O. Inhibition of human polymorphonuclear leukocyte functions by ibuprofen. Immunopharmacology 13 (1987) 61-71
101. Frazier J.L., Pradilla G., Wang P.P., and Tamargo R.J. Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. J Neurosurg 101 (2004) 93-98
102. Manno E.M., Gress D.R., Ogilvy C.S., Stone C.M., and Zervas N.T. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot study. Neurosurgery 40 (1997) 289-293
103. Chyatte D., Fode N.C., Nichols D.A., and Sundt Jr. T.M. Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 21 (1987) 157-160
104. Adams Jr. H.P., Brott T.G., Crowell R.M., Furlan A.J., Gomez C.R., Grotta J., et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 25 (1994) 1901-1914
105. Yanamoto H., Kikuchi H., Sato M., Shimizu Y., Yoneda S., and Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 30 (1992) 358-363
106. Dandy W. An operative procedure for hydrocephalus. Johns Hopkins Hosp Bull 22 (1922) 189
107. Hirashima Y., Endo S., Horie Y., and Kurimoto M. Indications for cisternal irrigation with urokinase in postoperative patients with aneurysmal subarachnoid haemorrhage. Br J Neurosurg 10 (1996) 477-481
108. Inagawa T., Kamiya K., and Matsuda Y. Effect of continuous cisternal drainage on cerebral vasospasm. Acta Neurochir (Wien) 112 (1991) 28-36
109. Ito U., Tomita H., Yamazaki S., Takada Y., and Inaba Y. Enhanced cisternal drainage and cerebral vasospasm in early aneurysm surgery. Acta Neurochir (Wien) 80 (1986) 18-23
110. Kasuya H., Shimizu T., and Kagawa M. The effect of continuous drainage of cerebrospinal fluid in patients with subarachnoid hemorrhage: a retrospective analysis of 108 patients. Neurosurgery 28 (1991) 56-59
111. Kawakami Y., and Shimamura Y. Cisternal drainage after early operation of ruptured intracranial aneurysm. Neurosurgery 20 (1987) 8-14
112. Komotar R.J., Olivi A., Rigamonti D., and Tamargo R.J. Microsurgical fenestration of the lamina terminalis reduces the incidence of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery 51 (2002) 1403-1412 [discussion 12-3]
113. Ogura K., Hara M., Tosaki F., and Hirai N. Effect of cisternal drainage after early operation for ruptured intracranial aneurysms. Surg Neurol 30 (1988) 441-444
114. Sakaki S., Ohta S., Kuwabara H., and Shiraishi M. The role of ventricular and cisternal drainage in the early operation for ruptured intracranial aneurysms. Acta Neurochir (Wien) 88 (1987) 87-94
115. Andaluz N., and Zuccarello M. Fenestration of the lamina terminalis as a valuable adjunct in aneurysm surgery. Neurosurgery 55 (2004) 1050-1059
116. Macdonald R.L. Pathophysiology and molecular genetics of vasospasm. Acta Neurochir Suppl 77 (2001) 7-11
117. Weir B., Macdonald R.L., and Stoodley M. Etiology of cerebral vasospasm. Acta Neurochir Suppl 72 (1999) 27-46
118. Klimo Jr. P., Kestle J.R., MacDonald J.D., and Schmidt R.H. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 100 (2004) 215-224
119. Suzuki I., Shimizu H., and Takahasi H. Head shaking method in cisternal irrigation for prevention of vasospasm. Surg Cereb Stroke 19 (1991) 295-300
120. Kawamoto S., Tsutsumi K., Yoshikawa G., Shinozaki M.H., Yako K., Nagata K., et al. Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 100 (2004) 236-243
121. Edwards D.H., Byrne J.V., and Griffith T.M. The effect of chronic subarachnoid hemorrhage on basal endothelium-derived relaxing factor activity in intrathecal cerebral arteries. J Neurosurg 76 (1992) 830-837
122. Sakowitz O.W., Wolfrum S., Sarrafzadeh A.S., Stover J.F., Dreier J.P., Dendorfer A., et al. Relation of cerebral energy metabolism and extracellular nitrite and nitrate concentrations in patients after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 21 (2001) 1067-1076
123. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272 (1997) 31725-31729
124. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
125. McGirt M.J., Lynch J.R., Parra A., Sheng H., Pearlstein R.D., Laskowitz D.T., et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 33 (2002) 2950-2956
126. Parra A., Kreiter K.T., Williams S., Sciacca R., Mack W.J., Naidech A.M., et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 56 (2005) 476-484 [discussion 76-84]
127. Zuccarello M., Marsch J.T., Schmitt G., Woodward J., and Anderson D.K. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 71 (1989) 98-104
128. Haley Jr. E.C., Kassell N.F., Alves W.M., Weir B.K., and Hansen C.A. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 82 (1995) 786-790
129. Haley Jr. E.C., Kassell N.F., Apperson-Hansen C., Maile M.H., and Alves W.M. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 86 (1997) 467-474
130. Asano T., Takakura K., Sano K., Kikuchi H., Nagai H., Saito I., et al. Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg 84 (1996) 792-803
131. Marshall J.W., Cummings R.M., Bowes L.J., Ridley R.M., and Green A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34 (2003) 2228-2233
132. Marshall J.W., Duffin K.J., Green A.R., and Ridley R.M. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32 (2001) 190-198
133. Marshall J.W., Green A.R., and Ridley R.M. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res 972 (2003) 119-126
134. Marshall J.W., and Ridley R.M. Assessment of cognitive and motor deficits in a marmoset model of stroke. Ilar J 44 (2003) 153-160
135. Lees K.R., Barer D., Ford G.A., Hacke W., Kostulas V., Sharma A.K., et al. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34 (2003) 482-487
136. Lees K.R., Sharma A.K., Barer D., Ford G.A., Kostulas V., Cheng Y.F., et al. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32 (2001) 675-680